Cover Image
市場調查報告書

異位性皮膚炎的全球市場分析

Global Atopic Dermatitis Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 360967
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎的全球市場分析 Global Atopic Dermatitis Market Report: 2016 Edition
出版日期: 2016年06月20日 內容資訊: 英文 61 Pages
簡介

本報告提供全球異位性皮膚炎相關市場相關分析,疾病概要和原因,主要的治療方法,全球市場結構和趨勢預測 (市場收益額、患者數等,今後9年份),各地區的詳細趨勢,推動及阻礙市場要素,近來的市場競爭狀況,主要企業簡介等調查評估。

第1章 異位性皮膚炎:概要

  • 異位性皮膚炎的症狀
  • 異位性皮膚炎的原因
  • 異位性皮膚炎的惡化要素
  • 濕疹的種類
  • 異位性皮膚炎患者的皮膚特徵
  • 異位性皮膚炎的分期 (階段)
  • 異位性皮膚炎的預防
  • 異位性皮膚炎的治療

第2章 異位性皮膚炎:全球市場

  • 異位性皮膚炎治療的全球市場 (以金額為準)
  • 成人的異位性皮膚炎的患者數:全球
  • 接受異位性皮膚炎治療的成人患者數:全球
  • 中∼重病的異位性皮膚炎的成人患者數:全球
  • 對局部療法有抵抗性的成人患者數:全球

第3章 異位性皮膚炎:各地區市場

  • 美國市場
    • 異位性皮膚炎治療的市場 (以金額為準)
    • 成人的異位性皮膚炎的患者數
    • 接受異位性皮膚炎治療的成人患者數
    • 中∼重病的異位性皮膚炎的成人患者數
    • 對局部療法有抵抗性的成人患者數
    • 接受治療的患者數
    • 異位性皮膚炎的重病度:各年齡層
  • 歐洲市場
    • 異位性皮膚炎治療的市場 (以金額為準)
    • 成人的異位性皮膚炎的患者數
    • 接受異位性皮膚炎治療的成人患者數
    • 中∼重病的異位性皮膚炎的成人患者數
    • 對局部療法有抵抗性的成人患者數
    • 接受治療的患者數
  • 其他的國家 (RoW)的市場
    • 異位性皮膚炎治療的市場 (以金額為準)
    • 中∼重病的異位性皮膚炎的成人患者數
    • 對局部療法有抵抗性的成人患者數

第4章 市場動態

  • 成長推動因素
  • 市場趨勢
  • 課題

第5章 競爭環境

  • 異位性皮膚炎治療用的開發平台生技藥品
  • 主要產品分析
    • Dupilumab
    • Nemolizumab
    • Lebrikizumab
    • Tralokinumab

第6章 企業簡介

  • Sanofi
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • GSK
  • AstraZeneca
  • Roche Holding

圖表一覽

目錄

Atopic dermatitis (AD) is a chronic, inflammatory skin disease of unknown origin that usually starts in early infancy, but also affects a substantial number of adults. Atopic dermatitis is a long lasting skin disease that affects a large percentage of the world's population and is a special type of hypersensitivity that is associated with asthma, inhalant allergies (hay fever), and a chronic dermatitis. The symptoms of atopic dermatitis are itching, red to brownish grey patches and small raised bumps.

The main cause of atopic dermatitis is unknown but it is assumed to be caused due to genetics, dry skin and environmental conditions. Multiple factors can trigger or worsen atopic dermatitis, including low humidity, seasonal allergies, exposure to harsh soaps and detergents, and cold weather. There has been no specified biologic till now for atopic dermatitis. But recent efforts by many companies have shown positive results and the first biologic may get launched in 2017. After that many other products are still in pipeline.

The key factors which are anticipated to drive atopic dermatitis market include increase in global population, improvement in the global health care expenditure, accelerated economic growth, pollution and climatic factors and role of triggers. Some of the significant developments of this industry include introduction of new biologics, biomarker in atopic dermatitis and opportunity for new entrants. However, the challenge to be faced ahead is time to be taken in drug adoption, high price and legal regulations.

This report offers a comprehensive analysis of the atopic dermatitis market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global market is reined by few major players namely Sanofi, Glaxo Smithkline (GSK), AstraZeneca and Roche Holding. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Atopic Dermatitis: An Introduction

  • 1.1 Symptoms of Atopic Dermatitis
  • 1.2 Causes of Atopic Dermatitis 8
  • 1.3 Factors which worsen Atopic Dermatitis
  • 1.4 Different Types of Eczema
  • 1.5 Skin Features of Atopic Dermatitis
  • 1.6 Stages of Atopic Dermatitis
  • 1.7 Prevention of Atopic Dermatitis
  • 1.8 Treatment of Atopic Dermatitis

2. Atopic Dermatitis - Global Market

  • 2.1 Global Atopic Dermatitis Treatment Market by Value
  • 2.2 Global Adults Affected with Atopic Dermatitis
  • 2.3 Global Adults Diagnosed with Atopic Dermatitis
  • 2.4 Global Adults with Moderate to Severe Atopic Dermatitis
  • 2.5 Global Adults Refractory to Topical Therapies

3. Atopic Dermatitis - Regional Markets

  • 3.1 The US Atopic Dermatitis Market
    • 3.1.1 The US Atopic Dermatitis Treatment Market by Value
    • 3.1.2 The US Adults Affected with Atopic Dermatitis
    • 3.1.3 The US Adults Diagnosed with Atopic Dermatitis
    • 3.1.4 The US Adults with Moderate to Severe Atopic Dermatitis
    • 3.1.5 The US Adults Refractory to Topical Therapies by Volume
    • 3.1.6 The US Treated Patients by Volume
    • 3.1.7 Severity Level for Atopic Dermatitis Patients for Different Age Groups
  • 3.2 European Union Atopic Dermatitis Market
    • 3.2.1 EU Atopic Dermatitis Treatment Market by Value
    • 3.2.2 EU Adults Affected with Atopic Dermatitis
    • 3.2.3 EU Adults Diagnosed with Atopic Dermatitis
    • 3.2.4 EU Adults with Moderate to Severe Atopic Dermatitis
    • 3.2.5 EU Adult Refractory to Topical Therapies by Volume
    • 3.2.6 EU Treated Patients by Volume
  • 3.3 ROW Atopic Dermatitis Market
    • 3.3.1 ROW Atopic Dermatitis Treatment Market by Value
    • 3.3.2 ROW Adults with Moderate to Severe Atopic Dermatitis
    • 3.3.3 ROW Adults Refractory to Topical Therapies by Volume

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increase in Global Population
    • 4.1.2 Increase in Health Care Expenditure
    • 4.1.3 Accelerated Economic Growth
    • 4.1.4 Pollution and Climate Factors
    • 4.1.5 Role of Triggers
  • 4.2 Trends and Development
    • 4.2.1 Introduction of New Biologics
    • 4.2.2 Biomarker in Atopic Dermatitis
    • 4.2.3 Opportunity for New Entrants
  • 4.3 Challenges
    • 4.3.1 Drug Adoption Takes Time
    • 4.3.2 High Price
    • 4.3.3 Legal Regulations

5. Competitive Landscape

  • 5.1 Pipeline Biologics for Atopic Dermatitis Treatment
  • 5.2 Key Product Analysis
    • 5.2.1 Dupilumab
    • 5.2.2 Nemolizumab
    • 5.2.3 Lebrikizumab
    • 5.2.4 Tralokinumab

6. Company Profiles

  • 6.1 Sanofi
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 GSK
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 AstraZeneca
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Roche Holding
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Atopic Dermatitis Treatment Algorithm
  • Global Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
  • Global Adults Affected with Atopic Dermatitis (2015-2025E)
  • Global Adults Diagnosed with Atopic Dermatitis (2015-2025E)
  • Global Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
  • Global Adults from Adult Refractory to Topical Therapies (2015-2025E)
  • The US Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
  • The US Adults Affected with Atopic Dermatitis (2015-2025E)
  • The US Adults Diagnosed with Atopic Dermatitis (2015-2025E)
  • The US Adult with Moderate to Severe Atopic Dermatitis (2015-2025E)
  • The US Adult Refractory to Topical Therapies (2015-2025E)
  • The US Treated Patients by Volume (2017E-2025E)
  • Severity Level for Atopic Dermatitis Patients for less than 5 years (2015)
  • Severity Level for Atopic Dermatitis Patients for 5 - 18 years (2015)
  • Severity Level for Atopic Dermatitis Patients for Greater than 18 years (2015)
  • Time Duration of Infection (2015)
  • Market Share of People Receiving Treatment (2015)
  • EU Atopic Dermatitis Treatment Forecast by Value (2018E-2025E)
  • EU Adults Affected with Atopic Dermatitis (2015-2025E)
  • EU Adults Diagnosed with Atopic Dermatitis (2015-2025E)
  • EU Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
  • EU Adult Refractory to Topical Therapies (2015-2025E)
  • EU Treated Patients by Volume (2018E-2025E)
  • ROW Atopic Dermatitis Treatment Forecast by Value (2017E-2025E)
  • ROW Adults with Moderate to Severe Atopic Dermatitis (2015-2025E)
  • ROW Adults Refractory to Topical Therapies (2015-2025E)
  • Global Population (2006-2015)
  • Global Health Care Expenditure (2007-2015E)
  • Improving Global GDP (2007-2015E)
  • Global Urban Population (2007-2015E)
  • Global Dupilumab Market by Value (2017E-2025E)
  • The US Dupilumab Market by Value (2017E-2025E)
  • European Union Dupilumab Market by Value (2018E-2025E)
  • Global Nemolizumab Market by Value (2019E-2025E)
  • The US Nemolizumab Market by Value (2019E-2025E)
  • European Union Nemolizumab Market by Value (2020E-2025E)
  • Global Lebrikizumab Market by Value (2019E-2025E)
  • The US Lebrikizumab Market by Value (2019E-2025E)
  • European Union Lebrikizumab Market by Value (2020E-2025E)
  • Global Tralokinumab Market by Value (2019E-2025E)
  • The US Tralokinumab Market by Value (2019E-2025E)
  • European Union Tralokinumab Market by Value (2020E-2025E)
  • Sanofi's Revenue Share by Segment (2015)
  • Sanofi's Revenue Share by Geography (2015)
  • Sanofi's Revenue and Net Income (2011-2015)
  • GSK's Revenue Share by Segment (2015)
  • GSK's Revenue Share by Geography (2015)
  • GSK's Revenue and Net Income (2011-2015)
  • AstraZeneca's Revenue Share by Segment (2015)
  • AstraZeneca's Revenue Share by Geography (2015)
  • AstraZeneca's Revenue and Net Income (2011-2015)
  • Roche's Revenue Share by Segment (2015)
  • Roche's Sales and Net Income (2011-2015)

List of Tables

  • Treatments Received by Patients
  • Pipeline Biologics for Atopic Dermatitis Treatment
Back to Top